# Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy

> **NCT01539681** · — · COMPLETED · sponsor: **Bayer** · enrollment: 234 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT01539681
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2014-01
- **Final completion:** 2015-02
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2016-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01539681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01539681, "Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01539681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*